Neurogenic dysphagia: current pharmacogenomic perspectives

Joaquin Guerra¹, Vinogran Naidoo², Ramón Cacabelos³

¹Neuro-Otolaryngology Unit, EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, Bergondo 15165, Corunna, Spain.
²Department of Neuroscience, International Center of Neuroscience and Genomic Medicine, EuroEspes Biomedical Research Center, Bergondo 15165, Corunna, Spain.
³Genomic Medicine, EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, Bergondo 15165, Corunna, Spain.

Correspondence to: Dr. Joaquin Guerra, Neuro-Otolaryngology Unit, EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine, Bergondo 15165, Corunna, Spain. E-mail: neuroorl@euroespes.com

How to cite this article: Guerra J, Naidoo V, Cacabelos R. Neurogenic dysphagia: current pharmacogenomic perspectives. J Transl Genet Genom 2022;6:304-21. https://dx.doi.org/10.20517/jtgg.2022.08

Received: 17 Mar 2022 First Decision: 17 May 2022 Revised: 18 May 2022 Accepted: 30 May 2022 Published: 1 Jul 2022

Abstract

Neurogenic dysphagia (ND) is characterized by a swallowing disorder where nervous system, muscle, and neuromuscular diseases are involved. DRD1, COMT, BDNF, and APOE are genes that may have a predictive role in the occurrence and evolution of ND. Many drugs that improve swallowing or can induce or exacerbate swallowing difficulties are related to dopamine metabolism and substance P. These pharmacological treatments for ND include dopamine precursors (levodopa), dopamine agonists (amantadine, apomorphine, cabergoline, and rotigotine), and TRP channel activators (capsaicin, piperine, and menthol). Since treatment outcomes are highly dependent on the genomic profiles of ND patients, personalized treatments should rely on pharmacogenetic procedures to optimize therapeutic interventions. Knowledge of the pharmacogenetic profiles of these drugs would minimize the occurrence of adverse drug reactions (especially to antidopaminergic medications) that may induce dysphagia and optimize pharmacological treatment that can ameliorate it. This knowledge should also be applied to the use of medications that control symptoms associated with dysphagia, such as sialorrhea, xerostomia, reflux, or hiccups.

Keywords: Oropharyngeal dysphagia, neurogenic dysphagia, pharmacogenomics, dopamine, dopaminergics, antidopaminergics, TRP genes
INTRODUCTION
Neurogenic dysphagia (ND) refers to any swallowing disorder associated with central and peripheral nervous system conditions, as well as muscle and neuromuscular diseases. ND is linked to multiple degenerative and nondegenerative congenital, traumatic, vascular, neoplastic, and iatrogenic disorders as diverse as cerebral palsy, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s syndromes, myasthenia gravis (MG), and myositis[1]. Based on clinical observations, ND can be classified into the following seven distinct phenotypes, which are particularly useful when etiological diagnosis is in doubt: (i) premature bolus spillage; (ii) delayed swallowing reflex, both characteristic of stroke; (iii) predominance of residue valleculae, common in patients with Parkinson’s disease; (iv) predominance of residue in the piriform sinus, characteristic of myositis, motor neuron disease, or brainstem stroke; (v) pharyngolaryngeal movement disorder, observed in patients with parkinsonism and stroke; (vi) fatigable swallowing weakness in individuals with myasthenia gravis; and (vii) complex disorder, as occurs in ALS[2].

The importance of dysphagia stems mostly from the increased risk of death caused by aspiration pneumonia, and conditions related to dehydration or malnutrition[3,4]. In addition to these factors, aging reduces the frequency of spontaneous swallowing[5]. To ensure proper diagnosis and management of ND, it is mandatory to: (i) obtain a complete medical history; (ii) perform screenings that assess the risk of aspiration (e.g., a swallowing test with water and other consistencies); (iii) conduct counseling tests and clinically evaluate dysphagia by videofluoroscopy (VFSS), swallowing endoscopy (FEES), or manometry, and other additional tests such as ultrasonography or electromyography); (iv) perform treatments based on dietary therapeutic interventions, behavioral interventions, oral hygiene measures, neurostimulation, pharmacotherapy, and surgical treatments[6]. In this third step, the management of special groups such as tracheostomized patients and patients with nasogastric tubes is of particular interest[6].

The treatment of ND is mainly based on rehabilitation therapies performed by speech therapists and other non-pharmacological approaches. However, some medications may be effective in improving impairment during the different phases of swallowing[6,7]. The majority of medications used to treat oropharyngeal dysphagia have a general effect on swallowing function that is independent of the underlying neurological disease; this allows for standardized use[6]. Pharmacotherapy, however, produces limited results and should therefore not be used as a stand-alone treatment, but rather as an adjunct to other therapies[6]. Furthermore, medications such as antidopaminergic agents, anticholinergic drugs, or benzodiazepines induce or exacerbate dysphagia[6-12].

In view of these considerations, research into specific ND-related genes may be useful in the prognosis of this condition. Because pharmacogenetics also plays a key role in both the diagnosis and the correct pharmacological management of patients with dysphagia, to increase the benefit of compounds that can improve swallowing difficulty and minimize the risk with the use of dysphagia-inducing drugs, in this review, we highlight these ND mechanisms from a pharmacogenomic perspective.

DOPAMINE AS A NEUROTRANSMITTER
Dopamine is a neurotransmitter of high relevance in the swallowing process. Its precursor, L-DOPA, is synthesized from the essential amino acid tyrosine or indirectly through phenylalanine, a non-essential amino acid. Dopamine β-hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine (NE), and NE is then converted into epinephrine by phenylethanolamine N-methyltransferase with S-adenosyl-L-methionine as the cofactor. Dopamine is degraded by monoamine oxidase (MAO-A and MAO-B), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), which act
Dopamine is synthesized and acts primarily in the central nervous system (CNS). Dopaminergic neurons project to different brain regions along the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways. Dopamine exerts its effects by binding to five G-protein-coupled receptors (D1-D5); of these, D1 receptors are the most abundant in the CNS. These receptors are divided into D1-like (D1 and D5) and D2-like (D2, D3, and D4) receptors. D1-like receptors exert a stimulatory effect through sodium channels or an inhibitory effect through potassium channels. At the peripheral level, dopamine does not cross the blood–brain barrier and is synthesized independently. Dopamine is present in plasma as dopamine sulfate, and only a small unconjugated amount can be synthesized by peripheral tissues.

**DOPAMINE AND SWALLOWING**

The swallowing process requires, at least in part, dopamine activity and its binding to its receptors. Although most dopamine receptors would theoretically be relevant to ND, the role of the dopamine D1 receptor (DRD1) is particularly important in this condition. For example, DRD1 antagonists alter the swallowing reflex and reduce substance P (SP) levels in peripheral organs. Specifically, in the striatum in an animal model of Huntington’s chorea, Drd1a, SP, and dynorphin expression is downregulated, whereas the expression of the dopamine D2 receptor (Drd2) and enkephalin is upregulated after ablation of D1 receptor-expressing cells. In this animal model, the resulting phenotype includes swallowing disturbances and poor oromotor coordination with tongue protrusion. This role of DRD1 has also been observed in certain single nucleotide polymorphisms (SNPs) in humans. The DRD1 rs4532 polymorphism confers a worse prognosis of swallowing function in individuals over the age of 65 following a stroke. Other SNPs, such as DRD2 rs1800497 and DRD3 rs6280, do not appear to be involved in ND. Moreover, interactions between the COMT rs165599 and BDNF rs10835211 polymorphisms are linked to dysphagia with increasing age; the effect of the SNP rs10835211 heterozygosity is dependent on the status of SNP rs165599.

**The use of dopaminergic agonists in the treatment of neurogenic dysphagia**

Levodopa, rotigotine, cabergoline, apomorphine, and amantadine are dopamine agonists that have been used generically to treat a variety of neurological conditions associated with oropharyngeal dysphagia. The drug that provides the best outcome is controversial because of conflicting outcomes across different studies. However, among these, levodopa is the most widely used, and it is also used to evaluate the swallowing response during the Fiberoptic Endoscopic Evaluation of Swallowing (FEES) test. Most studies have focused on the effect of dopaminergic agonists in Parkinson’s disease, and several publications show that these drugs improve dysphagia, especially in the oral phase and, to a lesser extent, in the pharyngeal phase. This clinical improvement is related to swallowing alterations due to nigrostriatal dopamine deficits and to other structures such as the pedunculopontine nucleus or the medulla. In a small group of patients, an improvement in bolus fragmentation, vallecular stasis, and laryngeal penetration was observed, together with a shortening of the swallowing phase; these findings are associated with an improvement in bucco-linguo-facial motility. Paradoxically, and despite most articles reporting a beneficial effect, one clinical trial showed that levodopa could worsen dysphagia by inhibiting brainstem reflexes. Overall, however, the results appear to support its use in PD patients despite the lack of high-quality evidence. Although dopaminergic agonists have a modest effect on the motor symptoms of progressive supranuclear palsy, they help some patients improve their swallowing. However, these drugs can also be employed in acquired neurological conditions. Following a lacunar stroke involving the basal ganglia, for example, levodopa decreases the risk of aspiration by shortening the latency of the swallowing reflex, as shown after examining the submental electromyographic activity and the visual observation of the laryngeal movement. This reduction, according to monocentric randomized trials in which imaging and
physical signs were evaluated, is also observed with other dopamine agonists such as cabergoline and amantadine; the elderly population, in particular, may benefit from treatment with dopamine agonists\textsuperscript{[30,31]}.

The search for new compounds to treat ND also includes natural supplements that contain dopamine, for use mainly in groups where dosage or side effects may be contraindicated, such as children or the elderly. Natural sources of dopamine include \textit{Mucuna pruriens}, \textit{Vicia faba}, or \textit{Musa cavendishii}\textsuperscript{[32-34]}. In fact, several studies in patients with Parkinson’s disease reveal the effectiveness of these treatments with extracts derived from these products; these compounds reduce the risk of adverse effects such as dyskinesias as well as induce epigenetic and pharmacoepigenetic modifications\textsuperscript{[35,36]}.

**Pharmacogenetics of dopaminergic agonists in the treatment of neurogenic dysphagia**

Anti-ND drugs exhibit different specific pharmacogenetic profiles (Table 1)\textsuperscript{[37]}. All of the medications used to treat ND show, among others, \textit{DRD1} as a mechanistic gene and the binding of drugs to this receptor. All of the anti-ND drugs have \textit{COMT} as substrates, where \textit{COMT} shortens the activity of these dopaminergic drugs\textsuperscript{[38]}. Moreover, the \textit{COMT} rs4680 polymorphism may induce motor complications such as dyskinesia during treatment with levodopa\textsuperscript{[39-40]}. Levodopa also has \textit{DBH} as substrate\textsuperscript{[37]}. \textit{ADORA2A} SNPs and \textit{HOMER1} variants are associated with L-DOPA-induced adverse motor (e.g., dyskinesia) and psychotic symptoms\textsuperscript{[41,42]}. A haplotype integrating -141CIns/Del, rs2283265, rs1076560, C957T, TaqIA, and rs2734849 polymorphisms at the \textit{DRD2}/\textit{ANKK1} gene region is linked to L-DOPA-induced motor dysfunction\textsuperscript{[43]}. \textit{SLC6A3} is a genetic modifier of the treatment response to L-DOPA\textsuperscript{[44]}. The multi-drug resistance gene (\textit{MDR1}) C1236T polymorphism may also influence pharmacotherapy\textsuperscript{[45]} and SNPs in genes that encode the dopamine transporter (\textit{DAT}; \textit{SLC6A3}) and the vesicular monoamine transporter 2 (\textit{VMAT2}; \textit{SLC18A2})\textsuperscript{[46]}. Despite the fact that dopamine agonist therapy has applicability in other ND diseases, these studies focus on Parkinson’s disease, which limits inferences in other acquired or degenerative neurological illnesses.

**Antidopaminergics and neurogenic dysphagia**

In a significant number of cases, the causes of ND can be induced or exacerbated by certain drugs\textsuperscript{[9-11]}. Many patients with different neurological conditions are treated with antidopaminergic medication\textsuperscript{[10,11]}. Adverse reactions are especially frequent in senescence and are relevant since they are reversible, and dysphagia may be the only or the predominant extrapyramidal symptom. Although it is recommended that drug intake be minimized as much as possible, this is not feasible in many cases. It is therefore recommended that the drug dose be adjusted to avoid the aforementioned side effects. Knowing the pharmacogenetic profiles of these drugs is, therefore, very important to therapeutic strategies\textsuperscript{[37]} (Table 2).

Antipsychotics, as antidopaminergic medications, are primarily metabolized through \textit{CYP1A2/2D6/3A4/2C19}\textsuperscript{[47]}. Of these, \textit{CYP2D6} is the most relevant because 40% of these neuroleptics are major substrates of this enzyme. \textit{CYP2D6}, however, is associated with side effects. Other genes such as \textit{HTR2A}, \textit{SLC18A2}, \textit{GRIK3}, and \textit{DRD2} are linked to extrapyramidal reactions\textsuperscript{[48]}. Drugs that exert an antidopaminergic effect on \textit{DRD1} are of particular interest. In ND, \textit{DRD1} is the pathogenic gene that is involved in the pharmacogenomic response to haloperidol, aripiprazole, olanzapine, quetiapine, or risperdone. Other \textit{DRDs} (not \textit{DRD1}) pathogenic variants mediate the adverse effects of antipsychotic drugs such as sulpiride, domperidone, and metoclopramide, causing oropharyngeal dysphagia; this suggests that other dopamine- and non-dopamine pathways mediate blocking of the swallowing phase\textsuperscript{[49]}.

**TRANSIENT RECEPTOR POTENTIAL CHANNEL (TRP) GENES**

Transient receptor potential (TRP) channel genes encode ion channels that are classified into two broad groups: (i) Group 1 includes TRPC (canonical), TRPV (vanilloid), TRPV1 (vanilloid-like), TRPM
| Drug     | Properties                                      | Pharmacogenetics                                      |
|----------|-------------------------------------------------|-------------------------------------------------------|
| Levodopa | IUPAC Name: L-Tyrosine-3-hydroxy                | Pathogenic genes: ANKK1, BDNF, LRRK2, PARK2           |
|          | Molecular Formula: C\textsubscript{9}H\textsubscript{11}NO\textsubscript{4} | Mechanistic genes: CCK, CCKAR, CCKBR, DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2A, GRIN2B, HCR7, HOMER, LMO3, OPRM1 |
|          | Molecular Weight: 197.19 g/mol                   | Metabolic genes: Substrate: COMT, CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DBH, DDC, G6PD, MAOB, TH, UGT1A1, UGT1A9 |
|          | Mechanism: Levodopa circulates in the plasma to the blood–brain barrier, where it crosses and is then converted by striatal enzymes to dopamine. Carbidopa inhibits the peripheral plasma breakdown of levodopa by inhibiting its carboxylation, and thereby increases available levodopa at the blood–brain barrier. | Transporter genes: SLC22A1, SLC6A3, SLC15A1 (inhibitor), SLC22A1 (inhibitor), SLC7A5, SLC7A8 |
|          | Effect: Antiparkinsonian agents, dopamine precursors. | Pleiotropic genes: ACE, ACHE |
| Cabergoline | IUPAC Name: Ergoline-8β-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonil]-6-(2-propenyl) | Pathogenic genes: BDNF, GSK3B |
|          | Molecular Formula: C\textsubscript{26}H\textsubscript{37}N\textsubscript{5}O\textsubscript{2} | Mechanistic genes: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, AKT1, BDNF, CRNR1, DRD1, DRD2, DRD3, DRD4, DRD5, GSK3B, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7 |
|          | Molecular Weight: 451.60 g/mol                   | Metabolic genes: Substrate: COMT, CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4 (minor), CYP3A5, DDC |
|          | Mechanism: A long-acting dopamine receptor agonist. | Transporter genes: ABCB1 |
|          | Has high binding affinity for dopamine D2-receptors and lesser affinity for D1, α1- and α2-adrenergic, and serotonin (5-HT1 and 5-HT2) receptors. | |
|          | Reduces serum prolactin concentrations by inhibiting release of prolactin from the anterior pituitary gland (agonist activity at D2 receptors) | |
|          | Effect: Antiparkinsonian agents, ergot-derivative dopamine receptor agonists | |
| Rotigotine | Molecular Formula: C\textsubscript{19}H\textsubscript{25}NO\textsubscript{s} | Pathogenic genes: ANKK1, BDNF, LRRK2 |
|          | Molecular Weight: 315.47 g/mol                   | Mechanistic genes: CCK, CCKAR, CCKBR, DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2A, GRIN2B, HCR7, HOMER, LMO3, OPRM1, HTR1A, ADRA2B |
|          | Mechanism: A non-ergot dopamine receptor agonist with specificity for D3-, D2-, and D1-dopamine receptors. Although the precise mechanism of action of Rotigotine is unknown, it is believed to be due to stimulation of postsynaptic dopamine D2-type autoreceptors within substantia nigra in brain, leading to improved dopaminergic transmission in motor areas in basal ganglia, notably caudate nucleus/putamen regions. | Metabolic genes: Substrate: COMT, MAOB, CYP3A4, CYP2D6 |
|          | Effect: Antiparkinsonian agents, non-ergot-derivative dopamine receptor agonists | Inhibitor: CYP2D6, CYP2C19 |
| Apomorphine | Molecular Formula: C\textsubscript{17}H\textsubscript{17}NO\textsubscript{2}HCl\textsubscript{1/2}H\textsubscript{2}O | Transporter genes: SLC22A1, SLC6A3 |
|          | Molecular Weight: 312.79 g/mol                   | Pleiotropic genes: ACE, APOE |
|          | Mechanism: Stimulates postsynaptic D2-type receptors within the caudate-putamen in the brain | |
|          | Effect: Antiparkinsonian agents, non-ergot-derivative dopamine receptor agonists | |
| Amantadine | IUPAC Name: Tricyclo[3.3.1.13,7]decan-1-amine, hydrochloride | Pathogenic genes: PARK2 |
|          | Molecular Formula: C\textsubscript{10}H\textsubscript{17}NHCl | Mechanistic genes: ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C |
|          | Molecular Weight: 187.71 g/mol                   | Metabolic genes: Substrate: COMT, CYP1A2 (minor), CYP2B6, CYP2C9 (minor), CYP2C19 (minor), CYP2D6, CYP3A4 (minor), CYP3A5, DDC, UGT1A1, UGT1A9, SULT1A1, SULT1A2, SULT1A3, SULT1E1, SULT1B1 |
|          | Mechanism: Antiparkinsonian activity may be due to inhibition of dopamine reuptake into presynaptic | Inhibitor: CYP1A2 (weak), CYP2C19 (weak), CYP3A4 (weak) |
|          | Effect: Antiparkinsonian agents, non-ergot-derivative dopamine receptor agonists | Transporter genes: SLC18A2 |
|          | | |
|          | | |

Table 1. Pharmacogenetics of dopaminergic agonists in the treatment of neurogenic dysphagia
neurons or by increasing dopamine release from presynaptic fibers
Effect: Antiparkinsonian agents, adamantanes, dopamine agonists
Inhibitor: MAO
 Transporter genes: SLC22A1 (Substrate/inhibitor), SLC22A2 (Substrate/inhibitor)

(melastatin), TRPS (soromelastatin), TRPN (no mechanoreceptor potential C), and TRPA (ankyrin); (ii) Group 2 consists of TRPP (polycystic) and TRPML (mucolipin).[49] Some of these targets represent a therapeutic strategy of interest for dysphagia by stimulating areas that evoke the swallowing reflex. Group 1 genes are the most relevant where TRPV1, TRPA1, and TRPM8, for example, are involved in stimulation of thermal sensitivity and the release of CGRP and inflammatory mediators.[50] These receptors are expressed on trigeminal, vagal, and glossopharyngeal nerve terminals; these nerves are critical in the swallowing process.[51,52] Three compounds of clinical relevance in ND that stimulate these receptors are capsaicin, piperine, and menthol. Capsaicin increases the frequency of spontaneous swallowing by stimulating TRPV1 receptors, piperine stimulates TRPV1/A1 receptors, and menthol stimulates TRPM8 receptors.[53,54] A recent meta-analysis revealed the effectiveness of TRP channel agonists in treating ND.[55] Capsaicin produces the highest therapeutic outcomes by lowering the risk of laryngeal penetration and pharyngeal residue and increasing bolus velocity.[54] Capsaicin also induces the release of SP, a neurotransmitter involved in amplifying the inflammatory response and nociceptive sensitization. Since DBH inhibits capsaicin, a pharmacogenetic study in patients with variants of interest is mandatory.[37] As mechanistic genes, TRPV1 Val585Ile and UCP2 -866 G/A variants correlate with the capsainoid therapeutic response.[56] All three, but mainly capsaicin, inhibit CYP group enzymes (CYP3A4, CYP2C9, and weak in CYP2D6). Furthermore, capsaicin and piperine inhibit CYP1A2.[57] In silico, piperine weakly inhibits CYP2D6 WT and CYP2D6*53.[58] Capsaicin and the other compounds, in addition to exhibiting large heterogeneity in their metabolic genes, exert anti-inflammatory effects by modulating pleiotropic genes such as TNF and ILs[37] [Table 3].

OTHER DRUGS USED IN NEUROGENIC DYSPHAGIA
Angiotensin-converting enzyme inhibitors (ACE inhibitors) inhibit substance P degradation.[59] These drugs reduce the cough threshold and subsequently can be used in aspiration prophylaxis; however, results from studies on perindopril, lisinopril, or imidapril are inconclusive.[60-61] Imidapril is effective in controlling dysphagia after stroke.[62] In one study, levetiracetam was beneficial to the recovery of dysphagia in post-stroke patients.[63] Several reports describe the usefulness of cough provocation tests with irritants (citric acid, tartaric acid, and mannitol) as a diagnostic tool,[64-65], but it remains to be determined whether such agents are useful for treating dysphagia. Table 3 shows the pharmacogenetic profiles of other drugs used to treat ND.[66] It should furthermore be noted that drugs used to treat ND (including dopaminergic agonists) may influence neuroplasticity and axonal regrowth or sprouting to improve, for example, the level of consciousness that would facilitate swallowing.[66].

OTHER GENES RELATED TO NEUROGENIC DYSPHAGIA
Few reports have linked other genes to dysphagia. However, the BDNF gene has been studied the most in this regard; the influence of the COMT gene on symptomatic dysphagia has been previously discussed.[67] rs6265 polymorphisms exert disparate effects on pharyngeal stimulation in healthy subjects[67] and appear to influence a better prognosis in swallowing after stroke or poor tolerance to esophageal electrostimulation in carriers of the Met allele.[69-70]. Furthermore, a study with a large sample of elderly individuals showed that e4 homozygous APOE carriers have low swallowing evaluation scores[71]. Finally,
| Drug          | IUPAC Name                                                                 | Molecular Formula | Molecular Weight | Mechanism                                                                                                                                         | Effect                                                                                     | Pharmacogenetics                                                                                     |
|--------------|---------------------------------------------------------------------------|-------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Haloperidol  | 4-[(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one | C_{21}H_{23}ClFNO_2 | 375.864223 g/mol  | It is a butyrophenone antipsychotic which blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in brain. Depresses release of hypothalamic and hypophyseal hormones. It is believed to depress reticular activating system. | Antipsychotic agent, Serotonergic antagonist, Dopaminergic antagonist, Antiemetic, Antidyskinesia agent, Sedative effects, Hypotension | ADRA1A, ADRA2A, ADRA2B, ADRA2C, BDNF, DRD1, DRD2, DRD3, DRD4, DTNBP1, GRIN2A, GRIN2B, GRIN2C, SLC6A3, MCHRN1, SLC18A2, HTR2C, SIGMAR1, HRH1, CHRM3, HTR1A, HTR6, HTR7                                                                                                |
| Sulpiride    | N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide            | C_{15}H_{23}N_3O_4S | 341.42582 g/mol   | It is a selective antagonist at postsynaptic D2 and D3 receptors. It appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or GABA receptors. It also stimulates secretion of prolactin. | Antipsychotic agent, Dopaminergic antagonist, Antidepressant effect, Antiemesis, Sedation (> 600 mg/day), Dopamine reuptake inhibition (< 200 mg/day), Antinermis, Antimigraine effects, Antivertiginous activity, Prolactin-releasing stimulation | DRD2, DRD3, DRD4, PRLH, CA2, CA3                                                                                                                 |
| Aripiprazole | 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one | C_{23}H_{27}Cl_2N_3O_2 | 448.38538 g/mol   | Partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptor | Antipsychotic agent, H1-receptor antagonist, Serotonergic agonist | DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR3A, HTR6, HTR7, CYP1A1                                                                                     |
| Olanzapine   | 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^3,7^]tetradeca-1(14),3(7),5,8,10,12-hexaene | C_{17}H_{20}N_4S   | 312.4325 g/mol    | It displays potent antagonism of serotonin 5-HT2A and 5-HT2C, dopamine D1-A, histamine H1 and H2-adrenergic receptors, moderate antagonism of 5-HT3 and muscarinic M1-5 receptors, and weak binding to GABA-A, BZD, and β-adrenergic receptors. | Antipsychotic agent, Antagonist modulator, Muscarinic antagonist, Serotonin uptake inhibitor, Dopaminergic antagonist, Serotonergic antagonist, Histamine antagonist, Antiemetic activity | DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR3A, HTR5, HTR6, HTR7, GABA-A, STAT3, TMEM163 |
Transporter genes: ABCB1 (substrate/inhibitor), KCNH2, SLC6A2, SLC6A4, SLCO3A1
Pleiotropic genes: APOA5, APOC3, GN23, LEP, LEPR, LPL
Pathogenic genes: ADR2A, DRD1, DRD2, DRD4, HTR1A, HTR2A, RGS4
Mechanistic genes: ADR1A, ADR1B, ADR2A, ADR2B, ADR2C, BDNF, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, D1R2, D2R2, D2R4, H1R1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6, HTR7
Metabolic genes: Substrate: CYP2D6 (minor), CYP3A4/5 (major), CYP3A7, CYP3A9
Transporter genes: ABCB1 (substrate/inhibitor), KCNE1, KCNE2, KCNE3, KCNQ1, SCN5A, SLC6A2 (inhibitor)

Pathogenic genes: ADR2A, BDNF, COMT, DRD1, DRD2, DRD3, DRD4, GRM3, HTR2A, HTR2C, HTR7, PON1, RGS4
Mechanistic genes: ADR1A, ADR1B, ADR2A, ADR2B, ADR2C, DRD1, DRD2, DRD3, DRD4, FOS, HRH1, HTR1A, HTR2A, HTR2C, HTR3A, HTR3C, HTR6, HTR7, NR1I2, STAT3
Metabolic genes: Substrate: COMT, CYP2D6 (major), CYP3A4/5 (minor)
Inhibitor: CYP2D6 (weak), CYP3A4 (weak)
Inducer: MAOB
Transporter genes: ABCB1 (substrate/inhibitor), KCNH2, SLC6A4
Pleiotropic genes: APOA5, BDNF, RGS2

Pathogenic genes: BDNF, DRD1, DRD2, DRD3, DRD4, HTR2A
Mechanistic genes: ADR1A, ADR1B, CHRM1, CHRM2, CHRM3, DRD1, DRD2, DRD3, DRD4, H1R1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCNQ1, SMPDI, CALM1
Metabolic genes: Substrate: CYP1A2 (minor), CYP2A6, CYP2C9, CYP2C19, CYP2D6 (major), CYP3A (minor), FMO1, UGT1A3, UGT1A4
Inhibitor: CYP1A2, CYP2D6 (strong), CYP2C19, CYP2E1 (weak), CYP3A4, DAO, BChE
Inducer: CYP3A4
Transporter genes: ABCB1 (substrate/inhibitor), ABCB11 (inhibitor), CTR
Pleiotropic genes: ACACA, BDNF, FABP1, LEP, NPY

Pathogenic genes: DRD2
Mechanistic genes: DRD2, CHRM1, HTR4, HTR3A
Metabolic genes: Substrate: CYP2D6 (minor), CYP3A4, CYP1A2 (minor)
Inhibitor: CYP2D6 (strong)
Transporter genes: ABCB1
Pleiotropic genes: ACH

---

Table 3. Pharmacogenetics of other drugs in the treatment of neurogenic dysphagia
| Drug            | Properties                                                                 | Pharmacogenetics                                                                 |
|-----------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Capsaicin       | Name: Capsaicin, 6-Nonenamide, (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl. Molecular Formula: \( \text{C}_{18}H_{27}\text{NO}_3 \). Molecular Weight: 305.41 g/mol. Mechanism: Induces release of substance P (main chemomediator of pain impulses from the periphery) from peripheral sensory neurons, depletes the neuron of substance P (after repeated stimulation), and prevents reaccumulation. Effect: Skin and Mucous Membrane Agents, local anesthetics, topical | Pathogenic genes: DBH, MPO, BCHE, TACR2, Mechanistic genes: TRPV1, PHB2, ABCB1, AC0X1, ACSL3, AOX5, CTR, F2, FOS, HTR1D, NOS3, NPC1, PPARA, TAC1, TGFBI, UCP2, Metabolic genes: Substrate: GLU, CYP2E1 (minor), UGT1A1, UGT1A7, UGT1A9, UGT1A10, GSTP1, Inhibitor: CYP3A4 (strong), CYP2C9, CYP2D6 (weak), PTGS2, MPO, CYP1A2 (strong), CYP1A1 (strong), CYP19A2 (strong), CYP2E1, DBH, BCHE, Inductor: CYP1A1, CYP1A2, Transporter genes: ABCB1. Pleiotropic genes: TNF. |
| Piperine         | Name: Piperine, IUPAC name: (2E,4E)-5-(2H-1,3-Benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one. Molecular Formula: \( \text{C}_{17}H_{19}\text{NO}_3 \). Molecular Weight: 285.34 g/mol. Mechanism: An alkaloid isolated from the plant Piper nigrum that has a role as an NF-kappaB inhibitor, a plant metabolite, a food component, and a human blood serum metabolite. It is a member of benzodioxoles, an N-acylpiperidine, a piperidine alkaloid, and a tertiary carboxamide. Effect: Skin and mucous membrane agents, local anesthetics, topical | Mechanistic genes: TRPV1, TRPA1, TRPM8, TOP1, FOS, Metabolic genes: Substrate: CYP1A1, Inhibitor: CYP3A4, CYP2C9, CYP2D6 (weak), Transporter genes: ABCB1 (inhibitor). Pleiotropic genes: TNF, IL1B, IL6. |
| Menthol         | Name: Menthol, IUPAC name: (1R,2S,5R)-2-isopropyl-5-methylcyclohexanol Molecular Formula: \( \text{C}_{10}H_{20}\text{O} \). Molecular Weight: 156.26 g/mol. Mechanism: A local anesthetic with counterirritant qualities, widely used to relieve minor throat irritation. Menthol also acts as a weak \( \kappa \)-opioid receptor agonist. Effect: Skin and mucous membrane agents, local anesthetics, topical | Mechanistic genes: TRPV1, TRPM8, TOP1, FOS, Metabolic genes: Substrate: CYP2A6. |
| Imidapril       | IUPAC name: (4S)-3-\{[2S]-2-[[2(S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl\}-1-methyl-2-oximidazolidine-4-carboxylic acid;hydrochloride Molecular Formula: \( \text{C}_{27}H_{27}\text{N}_{3}\text{O}_6 \). Molecular weight: 405.44 g/mol. Mechanism: Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Effect: Angiotensin-converting enzyme inhibitors. | Mechanistic genes: ACE, AGT, AGTR1, BDKR82, CES1, CES2, NOS3. |
| Lisinopril      | IUPAC name: L-Proline, 1-[N 2-(1-carboxy-3-phenylpropyl)-L-lysyl/]- dihydrate, (S) Molecular Formula: \( \text{C}_{21}H_{31}\text{N}_{3}\text{O}_5\text{H}_2\text{O} \). Molecular Weight: 441.52 g/mol. Mechanism: Competitive inhibitor of angiotensin-converting enzyme (ACE). Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Effect: Angiotensin-converting enzyme inhibitors. | Mechanistic genes: ACE, ACE2, REN, AGT, BDKR82, MMP3, NOS3, NPPA. Metabolic genes: Substrate: CYP3A4/5 (major). |
The T allele of rs17601696 (parent gene FGFR2) is reported to be associated with ND\textsuperscript{[72]}. 

**PHARMACOGENETICS OF DRUGS EMPLOYED IN OTHER ASSOCIATED OROPHARYNGEAL SYMPTOMS IN NEUROGENIC DYSPHAGIA**

Together with strategies aimed at controlling ND, it is also important to manage those factors that may exacerbate symptoms and increase the risk of aspiration. Many patients with CNS conditions exhibit sialorrhea, hiccups, xerostomia, or reflux with swallowing difficulties. Prior to considering systemic drugs, it is recommended that local treatment or physical measures be initiated first [Table 4]\textsuperscript{[37]}. 

**Sialorrhea**

The most used treatments for the control of hypersalivation in patients with neurological damage are based on their anticholinergic profiles. This includes a heterogeneous group of drugs such as amitriptyline, scopolamine, glycopyrronium chloride, trihexyphenidyl, atropine, or thiopium bromide. These anticholinergic agents present an added benefit in the control of other motor symptoms, as occurs in patients with Parkinson’s disease\textsuperscript{[73]}. However, their main drawback is the occurrence of frequent side effects that include sedation, cognitive deficits, constipation, urinary retention, tremor, and blurred vision. Within a population where the prevalence of dementia is high, elderly patients often use drugs with anticholinergic effects, and frequently in combination. Furthermore, in this patient population, polymedication may mask symptoms that are misdiagnosed as pathology unrelated to drug toxicity\textsuperscript{[74]}.

Concerning the pharmacogenetic profile, anticholinergic drug exposure shows associated variants located at chromosome 3p21.1 locus, with the top SNP rs1076425 in the inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) gene\textsuperscript{[75]}. Subjects with CYP2D6/CYP2C19 PM phenotype increase the risk of adverse reactions due to increased serum drug concentrations\textsuperscript{[76]}. In contrast, polymorphisms of the ARGEF10, ADRB3, ROCK2, and CYP3A4 genes in the cholinergic
### Table 4. Pharmacogenetics of drugs in associated symptoms and neurogenic dysphagia

| Drug                   | Properties                                                                                                                                  | Pharmacogenetics                                                                                                                                 |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| **Omeprazole**        | Name: Omeprazole. IUPAC name: 1H-Benzimidazole, 5-methoxy-2-[[4-(methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl] | Mechanistic genes: ATP4A, AHR, ADH1C, ALDH3A1, AHR, ATP4A, ATP4B, CASR, CBR1, CFTR, CHRM3, FMOL, HRH2, MMP2, NTR1I2, NTR1I3, RASS2, SNAP25, SSTR2 |
|                       | Molecular Formula: \(C_{17}H_{19}N_3O_3S\)                                                                                                  | Metabolic genes: Substrate: CYP1A1, CYP2C8 (minor), CYP2C9 (minor), CYP2C19 (major), CYP2D6 (minor). Inhibitor: CYP1A2, CYP2C9, CYP2D6 (moderate), CYP3A4, CYP2C19 (strong) |
|                       | Molecular weight: 345.42 g/mol                                                                                                               | Inducer: CYP1A1, CYP1B1, CYP3A4, CYP2B6. Transporter genes ABCG2 (inhibitor), ABCC3 (inducer), ABCB1, ABCC6 (substrate/inhibitor), ABCC6, UGT1A1 |
|                       | Mechanism: Concentrates in acid conditions of parietal cell secretory canaliculi. Forms active sulfenamide metabolite which irreversibly binds to and inactivates hydrogen-potassium ATPase (proton or acid pump), blocking final step in secretion of hydrochloric acid. Acid secretion is inhibited until additional hydrogen-potassium ATPase is synthesized, resulting in prolonged duration of action. Suppresses *H. pylori* in duodenal ulcer and/or reflex esophagitis infected with organism. Effect: Antiulcer agents and acid suppressants, proton-pump inhibitors, substituted benzimidazole |                                                                                     |
| **Pantoprazole**      | Name: Pantoprazole. IUPAC name: (1) 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]             | Mechanistic genes: ATP4A, DDAH1, ABC2, CASR, CHRM3, HRH2, IL1B, PPA5, SNAP25, SSTR2                                                                 |
|                       | Molecular Formula: \(C_{16}H_{15}F_2N_3O_4S\). Molecular weight: 383.37 g/mol                                                               | Metabolic genes: Substrate: CYP3A4 (major), CYP2C19, CYP2C9 (major), CYP2D6 (major). Inhibitor: CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (weak). Inducer: CYP1A2, CYP3A4. Transporter genes ABCB1 (substrate/inhibitor), ABCG2 (substrate/Inhibitor), SLC22A8 (inhibitor) |
|                       | Action: Suppresses gastric acid secretion by inhibiting parietal cell \(H^+K^+\) ATP pump                                                  |                                                                                     |
|                       | Effect: Antiulcer agents and acid suppressants, proton-pump inhibitors, substituted benzimidazole                              |                                                                                     |
| **Lansoprazole**      | Name: Lansoprazole. IUPAC name: 1H-Benzimidazole, 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl]sulfinyl]               | Mechanistic genes: ATP4A, DDAH1, ATP4B, CASR, CHRM3, HRH2, NTR1I2, NTR1I3, RASS2, SNAP25, SSTR2                                                                 |
|                       | Molecular Formula: \(C_{16}H_{14}F_3N_3O_2S\). Molecular weight: 369.36 g/mol                                                               | Metabolic genes: Substrate: CYP2C8 (major), CYP2C9 (major), CYP2C19 (major), CYP3A4/5 (major), POR. Inhibitor: CYP2C9 (moderate), CYP2D6 (moderate), CYP2E1 (moderate), CYP3A4 (moderate). Inducer: CYP1A2, CYP1A1, CYP2C9, CYP3A4. Transporter genes ABCG2 (inhibitor), ABCB1 (substrate/inhibitor), SLC22A8 (inhibitor), SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5                                                                 |
|                       | Action: Decreases acid secretion in gastric parietal cells through inhibition of \(H^+K^+\)-ATPase enzyme system, blocking final step in gastric acid production |                                                                                     |
|                       | Effect: Antiulcer agents and acid suppressants, proton-pump inhibitors, substituted benzimidazole                              |                                                                                     |
| **Rabeprazole**       | Name: Rabeprazole. IUPAC name: 1H-Benzimidazole, 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]                 | Mechanistic genes: ATP4A, DDAH1, ATP4B, CASR, CHRM3, HRH2, NTR1I2, NTR1I3, RASS2, SNAP25, SSTR2                                                                 |
|                       | Molecular Formula: \(C_{18}H_{20}N_3NaO_3S\). Molecular weight: 381.42 g/mol                                                               | Metabolic genes: Substrate: CYP3A4 (major), CYP2C19 (major), CYP2D6 (major). Inhibitor: CYP2C9 (moderate), CYP2D6 (moderate). Inducer: CYP1A2, CYP3A4. Transporter genes ABCG2 (inhibitor), ABCB1 (substrate/inhibitor), SLC22A8 (inhibitor), SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5                                                                 |
|                       | Action: Suppresses gastric acid secretion by inhibiting parietal cell \(H^+K^+\) ATP pump                                                  |                                                                                     |
|                       | Effect: Antiulcer agents and acid suppressants, proton-pump inhibitors, substituted benzimidazole                              |                                                                                     |
Name: Famotidine
IUPAC name: Propanimidamide, N'-(aminosulfonyl)-3-[[2-[[3-aminomethyl-4-thiazolyl]methyl]thio]-
Molecular formula: C_{26}H_{35}N_{7}O_{2}S_{3}
Molecular weight: 537.45 g/mol
Action: Famotidine works by reducing the amount of acid in the stomach, thereby reducing pain and allowing the ulcer to heal, and through a competitive inhibition of histamine at H2 receptors of gastric parietal cells, which inhibits gastric acid secretion.
Effect: Antiulcer agents and acid suppressants, histamine H2-antagonists

Name: Pilocarpine
IUPAC name:. 2(3H)-Furanone, 3-ethyldihydro-4-[[1-methyl-1H-imidazol-5-yl]methyl]-, monohydrochloride, (3S-cis)-
Molecular Formula: C_{11}H_{16}N_{2}O_{2}
Molecular weight: 244.72 g/mol
Mechanism: Directly stimulates cholinergic receptors in eye causing miosis (by contraction of iris sphincter) and loss of accommodation (by constriction of ciliary muscle) and lowering of intraocular pressure (with decreased resistance to aqueous humor outflow)
Effect: Antiglaucoma agents, miotics, cholinergic agonists

Name: Amitriptyline
IUPAC Name: dimethyl(3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
Molecular Formula: C_{20}H_{24}ClN
Molecular Weight: 313.86426 g/mol
Mechanism: Increases synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibiting their reuptake in the presynaptic neuronal membrane
Effect: Adrenergic uptake inhibition, antimigraine activity, analgesic (nonnarcotic) activity, antidepressant action

Name: Scopolamine
IUPAC Name: Benzeneacetic acid, α-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]non-7-yl ester, hydrobromide, trihydrate, [7(S)-(1\(\alpha\),2\(\beta\),4\(\beta\),5\(\alpha\),7\(\beta\))]-
Molecular Formula: C_{17}H_{21}NO_{4}HBr\cdot 3H_{2}O
Molecular weight: 438.31 g/mol
Mechanism: Competitively inhibits acetylcholine and other cholinergic stimuli at autonomic effectors innervated by postganglionic cholinergic nerves and, to a lesser extent, on smooth muscles that lack cholinergic innervation. Doses used to decrease gastric secretions likely to cause dryness of mouth (xerostomia). Antagonizes histamine and serotonin.
Effect: Anticholinergic agents, antimuscarinics/antispasmodics
Name: Glycopyrrolate  
IUPAC Name: Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide  
Molecular Formula: C_{19}H_{28}BrNO_{3}  
Molecular Weight: 398.33 g/mol  
Mechanism: Blocks action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and CNS  
Effect: Anticholinergic agents, antimuscarinics/antispasmodics

Name: Trihexyphenidyl  
IUPAC Name: 1-Piperidinepropanol, α-cyclohexyl-α-phenyl  
Molecular Formula: C_{20}H_{31}NO  
Molecular Weight: 301.46 g/mol  
Mechanism: Exerts direct inhibitory effect on parasympathetic nervous system. It also has a relaxing effect on smooth musculature, exerted both directly on muscle itself and indirectly through parasympathetic nervous system (inhibitory effect)  
Effect: Antiparkinsonian agents, anticholinergic agents

Name: Atropine  
IUPAC Name: Benzeneacetic acid, α-(hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-(–)  
Molecular Formula: C_{17}H_{23}NO_{3}  
Molecular Weight: 289.37 g/mol  
Mechanism: Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and CNS. Increases cardiac output, dries secretions. Reverses the muscarinic effects of cholinergic poisoning  
Effect: Mydriatics, anticholinergic agents, antimuscarinics/antispasmodics, antidote

Name: Domperidone  
IUPAC name: 2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-  
Molecular Formula: C_{22}H_{24}ClN_{5}O_{2}  
Molecular weight: 425.91 g/mol  
Mechanism: Has peripheral dopamine receptor blocking properties. Increases esophageal peristalsis; lowers esophageal sphincter pressure, gastric motility, and peristalsis; and enhances gastroduodenal coordination, therefore facilitating gastric emptying and decreasing small bowel transit time  
Effect: Prokinetic agents, dopamine antagonist

Name: Baclofen  
IUPAC name: Butanoic acid, 4-amino-3-(4-chlorophenyl)-  
Molecular Formula: C_{9}H_{12}ClNO  
Molecular weight: 213.66 g/mol  
Mechanism: Inhibits the transmission of mono/polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals  
Effect: GABA-derivative skeletal muscle relaxants

Mechanistic genes: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5  
Metabolic genes: Substrate: CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2C18, CYP2C19, CYP3A4  
Transporter genes: SLC22A2, SLC47A1  
Pathogenic genes: PARK2  
Mechanistic genes: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5  
Mechanistic genes: DRD2, DRD3  
Metabolic genes: Substrate: CYP3A4 (major), CYP3A7, CYP3A4 (major), CYP3A4 (minor), CYP2B6 (minor), CYP2CB6 (minor), CYB6 (major)  
Transporter genes: ABCB1  
Mechanistic genes: GABBR1, GABBR2, CXCR4, CFTR  
Transporter genes: ABCC9, ABCC12, SLC28A1

Pathway do not appear to significantly modify parameters related to clinical improvement.[77]

Xerostomia
The first line of treatment for xerostomia is to employ local therapies (artificial saliva, sialogogues), avoiding the use of systemic medications (pilocarpine) as the first choices due to their common negative effects. Side effects include blurred vision, bronchoconstriction, hiccup, sweating, hypotension, bradycardia,
cutaneous vasodilatation, nausea, diarrhea, or increased urinary frequency. Polymorphisms in CYP2A6 modify the pharmacokinetics of this drug, where the clearance of pilocarpine is significantly lower. In vivo, these slow metabolizers have two inactive CYP2A6 alleles: CYP2A6*4A, CYP2A6*7, CYP2A6*9, or CYP2A6*10.

Pharyngolaryngeal reflux
Proton-pump inhibitors (PPI) and H2 receptor antagonists show improvements in gastro-esophageal reflux disease-like symptoms, being PPIs more effective in subjects with negative endoscopic findings. CYP2C19 is the most prominent of the PPI-metabolizing enzymes; CYP2C19-specific single nucleotide polymorphisms reduce clearance proportionally and increase exposure and prolong proton-pump inhibition. Differences in CYP2C19-mediated metabolism lead to marked interpatient variability in acid suppression, drug–drug interaction potential, and clinical efficacy. This phenomenon has also been observed with CYP3A4, but to a lesser degree.

Hiccup
Pharmacologically, multiple drugs with different targets are available to control hiccups. Baclofen is a drug commonly used in intractable hiccups. The ABCC9 SNP (rs11046232, heterozygous AT versus reference TT genotype) is associated with a two-fold increase in oral baclofen clearance. Allelic variants with the ABCC12, SLC28A1, and PPARD SNPs generate variable responses in cerebral palsy. Chlorpromazine, domperidone, and metoclopramide can also be useful. However, since these are antidopaminergic drugs, they should be prescribed with caution because they may worsen dysphagia. Domperidone would be recommended amongst these medications because of its limited transit through the blood–brain barrier and exceptional central effects. Paradoxically, metoclopramide and other antidopaminergic drugs may be beneficial by reducing nausea and vomiting in patients with ND, and therefore the risk of aspiration. In these cases, dose adjustment and patient selection are essential due to the risk of adverse effects.

CONCLUSION
Treatment of ND must be comprehensive and multidisciplinary. Pharmacological treatments are support tools for other therapeutic measures. Dopamine is the main neurotransmitter implicated in these swallowing disorders. Of the genes that encode dopaminergic receptors, DRD1 is the most important in the prediction and treatment of ND. Other genes such as COMT and DBH have also been considered in the management of ND. Polymorphisms in dopaminergic and antidopaminergic agents are associated, respectively, with undesired or insufficient effects and increased risk of swallowing impairment. SP is another main factor in the treatment of ND, which can be altered with antidopaminergic agents. SP degradation is blocked with TRP channel agonists such as capsaicin, piperine, menthol, and ACE inhibitors. Genetic variants influence the therapeutic response of TRP channel agonists. When symptoms coexist that can worsen dysphagia and increase the risk of aspiration (e.g., reflux, xerostomia, sialorrhea, and hiccups), it is recommended to carefully associate other medications with ND treatment due to the risk of adverse effects, which may even include swallowing disorders. Dose adjustment and choice of drug in polypharmacy patients is one of the main objectives of a pharmacogenetic analysis.

DECLARATIONS
Acknowledgments
Joaquin Guerra would like to thank Dante Doncel Guerrero for being the source of inspiration to develop this article.
Authors’ contributions
Made substantial contributions to conception and design of the review and interpretation: Guerra J Read, adjusted and approved the final manuscript: Naidoo V, Cacabelos R

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Panebianco M, Marchese-Ragona R, Masiero S, Restivo DA. Dysphagia in neurological diseases: a literature review. *Neurol Sci* 2020;41:3067-73.  DOI PubMed PMC
2. Warnecke T, Labeit B, Schroeder J, et al. Neurogenic dysphagia: systematic review and proposal of a classification system. *Neurology* 2021;96:e876-89.  DOI PubMed
3. Sura L, Madhavan A, Carnaby G, Crary MA. Dysphagia in the elderly: management and nutritional considerations. *Clin Interv Aging* 2012;7:287-98.  DOI PubMed PMC
4. Wirth R, Dziewas R, Beck AM, et al. Oropharyngeal dysphagia in older persons - from pathophysiology to adequate intervention: a review and summary of an international expert meeting. *Clin Interv Aging* 2016;11:189-208.  DOI PubMed PMC
5. Nascimento W, Tomsen N, Acedo S, et al. Effect of aging, gender and sensory stimulation of TRPV1 Receptors with capsaicin on spontaneous swallowing frequency in patients with oropharyngeal dysphagia: a proof-of-concept study. *Diagnostics (Basel)* 2021;11:461.  DOI PubMed PMC
6. Dziewas R, Allescher HD, Aroyo I, et al. Diagnosis and treatment of neurogenic dysphagia - S1 guideline of the German society of neurology. *Neuro Res Pract* 2021;3:23.  DOI PubMed PMC
7. Speyer R, Baijens L, Heijnen M, Zwijnenberg I. Effects of therapy in oropharyngeal dysphagia by speech and language therapists: a systematic review. *Dysphagia* 2010;25:40-65.  DOI PubMed PMC
8. Warnecke T, Dziewas R, Langmore S. Neurogenic dysphagia. 1st ed. Cham: Springer, 2021.8
9. Stoschus B, Allescher HD. Drug-induced dysphagia. *Dysphagia* 1993;8:154-9.  DOI PubMed
10. Sokoloff LG, Pavlakovic R. Neuroleptic-induced dysphagia. *Dysphagia* 1997;12:177-9.  DOI PubMed
11. Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. *Ment Health Clin* 2017;7:56-64.  DOI PubMed PMC
12. Wolf U, Eckert S, Walter G, et al. Prevalence of oropharyngeal dysphagia in geriatric patients and real-life associations with diseases and drugs. *Sci Rep* 2021;11:21955.  DOI PubMed PMC
13. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. *Pharmacol Rev* 2004;56:331-49.  DOI PubMed
14. Vidal P-P, Sans A. Chapter 30: Vestibular system. In: Paxinos G, editor. The rat nervous system, 3dr ed. London: Academic Press, 2004; pp. 965-96.
15. Tritsch NX, Sabatini BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. *Neuron* 2012;76:33-50.  DOI PubMed PMC
16. Bieger D, Giles S, Hockman C. Dopaminergic influences on swallowing. *Neuropsychopharmacology* 1977;16:245-52.  DOI PubMed
17. Jia YX, Sekizawa K, Ohrui T, Nakayama K, Sasaki H. Dopamine D1 receptor antagonist inhibits swallowing reflex in guinea pigs. *Am J Physiol* 1998;274:R76-80.  DOI PubMed
18. Gantois I, Fang K, Jiang L, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. *Proc Natl Acad Sci USA* 2007;104:4182-7. DOI PubMed PMC
19. Park HY, Kim Y, Oh HM, Kim TW, Park GY, Im S. Potential prognostic impact of dopamine receptor d1 (rs4532 ;12:675060. DOI PubMed PMC
20. Nimmons D, Pendleton N, Payton A, et al. A novel association between COMT and BDNF gene polymorphisms and likelihood of symptomatic dysphagia in older people. *Neurogastroenterol Motil* 2015;27:1223-31. DOI PubMed
21. Warnecke T, Oelenberg S, Teissmann I, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. *Mov Disord* 2010;25:1239-45. DOI PubMed
22. Warnecke T, Suttrop I, Schröder JB, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. *Parkinsonism Relat Disord* 2016;28:108-6. DOI PubMed
23. Hunter PC, Cramer J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. *J Neurol Neurosurg Psychiatry* 1997;63:579-83. DOI PubMed PMC
24. Hirano M, Isono C, Sakamoto H, Ueno S, Kusunoki S, Nakamura Y. Rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson’s disease. *Dysphagia* 2019;30:452-6. DOI PubMed
25. Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusunoki S. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease. *J Neurol* 2019;404:5-10. DOI PubMed
26. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. *Mov Disord* 1996;11:729-32. DOI PubMed
27. Michou E, Hamdy S, Harris M, et al. Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with Parkinson’s disease. *Clin Gastroenterol Hepatol* 2014;12:2037-45.e1. DOI PubMed
28. Chang MC, Park JS, Lee BJ, Park D. Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review. *Neuro Sci* 2021;42:513-9. DOI PubMed
29. Kobayashi H, Nakagawa T, Sekizawa K, Arii H, Sasaki H. Levodopa and swallowing reflex. *Lancet* 1996;348:1320-1. DOI PubMed
30. Arii T, Sekizawa K, Yoshimi N, Toshima S, Fujiwara N. Cabezoligne and silent aspiration in elderly patients with stroke. *J Am Geriatr Soc* 2001;51:1815-6. DOI PubMed
31. Nakagawa T, Wada H, Sekizawa K, Arii H, Sasaki H. Amantadine and pneumonia. *Lancet* 1999;353:1157. DOI PubMed
32. Apaydin H, Ertan S, Ozcakmucuk S. Broad bean (Vicia faba) - A natural source of L-dopa-Prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations. *Mov Disord* 2000;15:164-6. DOI
33. Kanazawa K, Sakakibara H. High content of dopamine, a strong antioxidant, in Cavendish banana. *J Agric Food Chem* 2000;48:844-8. DOI PubMed
34. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. *Sci Rep* 2015;5:11078. DOI PubMed
35. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. *J Neurol Neurosurg Psychiatry* 2004;75:1672-7. DOI PubMed PMC
36. Cabrelos R, Carrera I, Martinez O, et al. Atremorine in parkinson’s disease: from dopaminergic neuroprotection to pharmacogenomics. *Med Res Rev* 2021;41:2841-86. DOI PubMed
37. Cabrelos R. World guide for drug use and pharmacogenomics. Corunna, Spain: EuroEspes Publishing Co., 2012.
38. Soler-Alfonso C, Motil KJ, Turk CL, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. *Mov Disord* 2010;25:1239-45. DOI PubMed
39. Warnecke T, Suttrop I, Schröder JB, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. *Parkinsonism Relat Disord* 2016;28:108-6. DOI PubMed
40. Hunter PC, Cramer J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. *J Neurol Neurosurg Psychiatry* 1997;63:579-83. DOI PubMed PMC
41. Hirano M, Isono C, Sakamoto H, Ueno S, Kusunoki S, Nakamura Y. Rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson’s disease. *Dysphagia* 2019;30:452-6. DOI PubMed
42. Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusunoki S. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease. *J Neurol* 2019;404:5-10. DOI PubMed
43. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. *Mov Disord* 1996;11:729-32. DOI PubMed
44. Michou E, Hamdy S, Harris M, et al. Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with Parkinson’s disease. *Clin Gastroenterol Hepatol* 2014;12:2037-45.e1. DOI PubMed
45. Chang MC, Park JS, Lee BJ, Park D. Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review. *Neuro Sci* 2021;42:513-9. DOI PubMed
46. Kobayashi H, Nakagawa T, Sekizawa K, Arii H, Sasaki H. Levodopa and swallowing reflex. *Lancet* 1996;348:1320-1. DOI PubMed
47. Arii T, Sekizawa K, Yoshimi N, Toshima S, Fujiwara N. Cabezoligne and silent aspiration in elderly patients with stroke. *J Am Geriatr Soc* 2001;51:1815-6. DOI PubMed
48. Nakagawa T, Wada H, Sekizawa K, Arii H, Sasaki H. Amantadine and pneumonia. *Lancet* 1999;353:1157. DOI PubMed
49. Apaydin H, Ertan S, Ozcakmucuk S. Broad bean (Vicia faba) - A natural source of L-dopa-Prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations. *Mov Disord* 2000;15:164-6. DOI
50. Kanazawa K, Sakakibara H. High content of dopamine, a strong antioxidant, in Cavendish banana. *J Agric Food Chem* 2000;48:844-8. DOI PubMed
51. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. *Sci Rep* 2015;5:11078. DOI PubMed
52. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. *J Neurol Neurosurg Psychiatry* 2004;75:1672-7. DOI PubMed PMC
53. Cabrelos R, Carrera I, Martinez O, et al. Atremorine in parkinson’s disease: from dopaminergic neuroprotection to pharmacogenomics. *Med Res Rev* 2021;41:2841-86. DOI PubMed
54. Cabrelos R. World guide for drug use and pharmacogenomics. Corunna, Spain: EuroEspes Publishing Co., 2012.
55. Soler-Alfonso C, Motil KJ, Turk CL, et al. Potomiction of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. *Movement Disorders* 2013;28:1271-83. DOI PubMed
56. Ahmed SS, Husain RS, Kumar S, Ramakrishnan V. Association between MDR1 gene polymorphisms and Parkinson’s disease in Asian and Caucasian populations: a meta-analysis. *J Neurol Sci* 2016;368:255-62. DOI PubMed
57. Lohr KM, Masoud ST, Salahpour A, Miller GW. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. *Eur J Neurosci* 2017;45:20-33. DOI PubMed
58. Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. *Dialogues Clin Neurosci* 2014;16:555-66. DOI PubMed
59. Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. *Mol Neuropsychiatry* 2020;5:1-26. DOI PubMed PMC
50. Venkatachalam K, Montell C. TRP channels. *Annu Rev Biochem* 2007;76:387-417. DOI PubMed PMC

51. Kichko TI, Neuhuber W, Kobal G, Reeh PW. The roles of TRPV1, TRPA1 and TRPM8 channels in chemical and thermal sensitivity of the mouse oral mucosa. *Eur J Neurosci* 2018;47:201-10. DOI PubMed

52. Alvarez-Berduo D, Rofes L, Farré R, et al. Localization and expression of TRPV1 and TRPA1 in the human oropharynx and larynx. *Neurogastroenterol Motil* 2016;28:91-100. DOI PubMed

53. Hossain MZ, Ando H, Unno S, Masuda Y, Kitagawa J. Activation of TRPV1 and TRPM8 channels in the larynx and associated laryngoopharyngeal regions facilitates the swallowing reflex. *Int J Mol Sci* 2018;19:4113. DOI PubMed PMC

54. Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that senses cold stimuli and menthol. *Cell* 2002;108:705-15. DOI PubMed

55. Hoshino M, Kojima N, Saeki K, Ishihara M, Takayama M. Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia. *Eur J Pharmacol* 2015;746:126-31. DOI PubMed

56. Shamsi S, Tran H, Tan JZ, Lim LY. Curcumin, piperine, and capsaicin: a comparative study of spice-mediated inhibition of human cytochrome P450 isozyme activities. *Drug Metab Dispos* 2017;45:49-55. DOI PubMed PMC

57. Snitker S, Fujishima Y, Shen H, et al. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. *Am J Clin Nutr* 2009;89:45-50. DOI PubMed PMC

58. Venkatachalam K, Montell C. TRP channels. *Annu Rev Biochem* 2011;80:141-827-836.e1. DOI PubMed

59. Oh HM, Kim TW, Park HY, Kim Y, Park GY, Im S. Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study. *Neurogastroenterol Motil* 2021;33:e13953. DOI PubMed

60. Vasant DH, Payton A, Mistry S, Thompson DG, Hamdy S. The val66met polymorphism of brain-derived neurotrophic factor is associated with human esophageal hypersensitivity. *Neurogastroenterol Motil* 2013:25:162-e85. DOI PubMed

61. Essa H, Vasant D, Ragins-zborowska A, Payton A, Michou E, Hamdy S. PTU-182 Can response to pharyngeal stimulation in human cytochrome P450 isozyme activities. *Drug Metab Dispos* 2017;45:49-55. DOI PubMed PMC

62. Don CG, Smieško M. DOI PubMed PMC

63. Ikeda J, Kojima N, Saeki K, Ishihara M, Takayama M. Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia. *Eur J Pharmacol* 2015;746:126-31. DOI PubMed

64. Shindo H, Shiba Y, Orita H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. *Adv Ther* 2012;29:900-12. DOI PubMed

65. Lee JS, Chui PY, Ma HM, et al. Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia - a randomized placebo-controlled trial. *J Am Med Dir Assoc* 2015;16:702-7. DOI PubMed

66. Chen D, Xing H, Jiang Q, Xian Y, Hu W, Guo H. Role of levotiretacem in the rehabilitation of dysphagia due to stroke. *Int J of Pharmacol* 2017;13:603-11. DOI

67. Monroe MD, Manco K, Bennett R, Huckabee M. Citric acid cough reflex test: Establishing normative data. *J Speech Lang Hear Res* 2014;17:216-24. DOI

68. Fujiwara K, Kawamoto K, Shimizu Y, et al. A novel reflex cough testing device. *BMC Pulm Med* 2017;17:19. DOI PubMed PMC

69. Nurmi HM, Lättilä AM, Brannan JD, Koskela HO. Comparison of mannitol and citric acid cough provocation tests. *Respir Med* 2019;158:14-20. DOI PubMed

70. Krieger DW. Therapeutic drug approach to stimulate clinical recovery after Brain injury. *Front Neurol Neurosci* 2013;76:87. DOI PubMed

71. Jayasekeran V, Pendleton N, Holland G, et al. Val66Met in brain-derived neurotrophic factor affects stimulus-induced plasticity in the human pharyngeal motor cortex. *Gastroenterology* 2011;141:827-836.e1. DOI PubMed

72. Venkatachalam K, Montell C. TRP channels. *Annu Rev Biochem* 2011;80:141-827-836.e1. DOI PubMed

73. Oh HM, Kim TW, Park HY, Kim Y, Park GY, Im S. Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study. *Neurogastroenterol Motil* 2021;33:e13953. DOI PubMed

74. Vasant DH, Payton A, Mistry S, Thompson DG, Hamdy S. The val66met polymorphism of brain-derived neurotrophic factor is associated with human esophageal hypersensitivity. *Neurogastroenterol Motil* 2013:25:162-e85. DOI PubMed

75. Essa H, Vasant D, Ragins-zborowska A, Payton A, Michou E, Hamdy S. PTU-182 Can response to pharyngeal stimulation in dysphagic stroke be predicted by bdnf genetic polymorphisms? *Gut* 2015;64:A143.1-A143. DOI

76. Mentz H, Horan M, Payton A, Ollier W, Pendleton N, Hamdy S. Homozygosity in the ApoE 4 polymorphism is associated with dysphagic symptoms in older adults. *Dis Esophagus* 2015;28:97-103. DOI PubMed

77. Ragins-zborowska A, Mekli K, Payton A, Ollier W, Hamdy S, Pendleton N. Genetic determinants of swallowing impairments among community dwelling older population. *Exp Gerontol* 2015;69:196-201. DOI PubMed

78. Katzenschlager R, Sampao C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. *Cochrane Database Syst Rev* 2003;2002:CD003735. DOI PubMed PMC

79. Schuh MJ, Crosby S. Chronic anticholinergic toxicity discovered in a pharmacogenomics, polypharmacy patient. *Sr Care Pharm* 2021;36:304-10. DOI PubMed

80. Emt S, Hill SK, Alliey-Rodriguez N, et al. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. *Neuropsychopharmacology* 2021;46:1802-10. DOI PubMed PMC

81. Kersten H, Wyller TB, Molden E. Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs. *Ther Drug Monit* 2014;36:125-30. DOI PubMed

82. Gurocak S, Konac E, Ure I, et al. The impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder. *Dis Markers* 2015;2015:732686. DOI PubMed PMC

83. Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. *Ther Clin Risk Manag* 2015;11:45-51. DOI PubMed PMC

84. Endo T, Nakajima M, Fukami T, et al. Genetic polymorphisms of CYP2A6 affect the in vivo pharmacokinetics of pilocarpine.
Pharmacogenet Genomics 2008;18:761-72. DOI PubMed
80. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013;5:CD002095. DOI PubMed PMC
81. Addington WR, Stephens RE, Gilliland K, Miller SP. Tartaric acid-induced cough and the superior laryngeal nerve evoked potential. Am J Phys Med Rehabil 1998;77:523-6. DOI PubMed
82. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013;15:119-31. DOI PubMed PMC
83. Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018;14:447-60. DOI PubMed PMC
84. Harris DM, Stancampiano FF, Burton MC, et al. Use of pharmacogenomics to guide proton pump inhibitor therapy in clinical practice. Dig Dis Sci 2021;66:4120-7. DOI PubMed
85. Patial RK. Baclofen in the treatment of intractable hiccups. J Assoc Physic India 2002;50:1312-3.
86. McLaughlin MJ, He Y, Brunstrom-Hernandez J, et al. Pharmacogenomic variability of oral baclofen clearance and clinical response in children with cerebral palsy. PMR 2018;10:235-43. DOI PubMed PMC
87. Ferrier J. Domperidone as an unintended antipsychotic. Can Pharm J (Ott) 2014;147:76-7. DOI PubMed PMC